A new study published in the British Journal of Ophthalmology looked at whether metformin, taken by mouth, can reach the lens capsule of the eye and affect the cell activity that leads to posterior capsule opacification (PCO).
The findings suggest the drug may slow the activity of lens epithelial cells at levels used in real-world treatment, pointing to a potential pharmacological approach to reduce this common post-cataract complication.
Let’s start with the basics: Why does posterior capsule opacification develop after cataract surgery?
PCO is the most common long-term complication following cataract surgery, affecting roughly 20% to 30% of patients within 5 years post-surgery.
It develops when residual lens epithelial cells left behind after surgery begin to proliferate, migrate and transform, eventually clouding the posterior capsule and reducing visual clarity.
These cellular changes are part of a wound-healing response, but in this case, they lead to fibrosis or pearl-like opacities that interfere with vision.
Why are researchers looking at medications like metformin for PCO prevention?
Current prevention methods mostly rely on the design of intraocular lenses to physically block cell movement. While this helps, it does not fully eliminate the risk.
Metformin has gained attention because it can reduce scarring and slow cell growth in different parts of the body.
- In fact: Earlier studies have also linked metformin use to lower rates of Nd:YAG laser capsulotomy, a procedure used to treat PCO. This has led researchers to explore whether the drug can directly affect how lens epithelial cells behave inside the eye.
So where does this new research come in?
Well, there were two topics in question: whether metformin actually reaches the human lens capsule in measurable amounts, and whether those concentrations are sufficient to affect the cells responsible for PCO.
To do that, researchers combined clinical tissue analysis with laboratory experiments to connect systemic drug exposure with biological activity at the cellular level.
How was the study designed?
The study used a dual approach.
- First: Researchers measured metformin levels in both blood and lens capsule tissue collected during cataract surgery in patients with type 2 diabetes (T2D) taking the drug.
- Second: They conducted laboratory experiments using human lens capsule samples cultured with and without metformin to directly observe how the drug affects cell proliferation over time.
Who was included in the study?
The clinical portion included 20 patients with T2D undergoing routine cataract surgery while taking oral metformin.
For the laboratory portion, anterior lens capsules from non-diabetic donors were used to isolate the drug’s effect without confounding systemic factors.
What did the researchers find about metformin in the lens capsule?
Metformin was found in all lens capsule samples, confirming that the drug, when taken systemically, can reach intraocular tissue.
The study also found a significant correlation between metformin levels in the blood and those in the lens capsule, suggesting that systemic exposure translates into measurable concentrations at the site of interest.
Interestingly, capsule concentrations were similar regardless of whether patients were taking lower or higher doses.
Did metformin actually affect lens epithelial cell behavior?
Yes, and this is the key finding. In laboratory experiments, metformin significantly reduced the proliferation of lens epithelial cells compared with untreated controls.
While cell growth was not completely stopped, it was clearly attenuated over time, indicating that even low concentrations of metformin may influence the cellular processes that drive PCO.
What mechanisms might explain metformin’s potential protective effect?
Metformin affects several biological pathways involved in cell growth and scarring:
- It activates AMP-activated protein kinase and blocks pathways linked to cell growth and inflammation
- In the lens capsule, these effects may help limit the abnormal cell activity that leads to clouding after surgery
Any limitations to consider when interpreting the findings?
The study was relatively small, with a limited number of surgical samples. It also combined in vivo drug measurements with in vitro experiments.
- What this means: The results do not directly demonstrate clinical reduction in PCO rates. Instead, they provide early mechanistic evidence.
Additional studies with larger patient populations and long-term clinical outcomes would be needed to confirm whether these effects translate into meaningful benefits after surgery.
How do these findings compare with previous research?
Previous research on diabetes and PCO has produced mixed results, with some studies suggesting a protective effect and others showing increased risk.
One explanation for these inconsistencies is that earlier work often did not account for differences in diabetes treatment.
- This study adds to emerging evidence that metformin itself, rather than diabetes alone, may influence PCO-related processes.
Why might this matter for future cataract surgery outcomes?
If larger studies confirm metformin’s effects on lens epithelial cells, it could lead to new ways to prevent PCO.
These could include using the drug in certain patients or delivering it directly into the eye—such as through drug-eluting intraocular lenses—to target the underlying cause rather than relying only on mechanical barriers.
Take home.
This study provides early evidence that systemically administered metformin reaches the human lens capsule and can reduce the proliferation of cells responsible for posterior capsule opacification.
While clinical impact remains to be established, the findings suggest a potential future role for pharmacologic strategies alongside existing surgical approaches to PCO prevention.